UC profs call for more vitamin D
This article was originally published in The Tan Sheet
Most adults should be consuming 2,000 IU of vitamin D daily, far above current recommended levels, according to a group of 18 University of California researchers. UC Riverside says Nov. 13 that professor emeritus of biochemistry and of biomedical sciences Anthony Norman, along with UC San Diego professor Cedric Garland, are leading a "call to action" to increase the recommended dosage of vitamin D, currently 200 IU for people up to age 50. The scientists note vitamin D helps reduce the risk of cancer, type 1 diabetes and cardiovascular disease. Most people obtain insufficient vitamin D from fortified foods and sun exposure, they add. In a study published in 2007, Garland identified a link between high blood levels of 25-hydroxyvitamin D and a 50 percent drop in breast cancer risk (1"The Tan Sheet" Feb. 12, 2007, p. 16)
You may also be interested in...
Total Nutraceutical Solutions acquires an option to license a patented invention from Penn State University that can increase the vitamin D2 in mushrooms by up to 800 percent via pulsed UV light, the Spartanburg, S.C.-based firm says Nov. 24. "This breakthrough vitamin D technology is a perfect fit for our company, [which focuses on] the use of natural mushrooms and their contained bioactive components as a whole food approach to the prevention of disease," says TNS CEO Marvin S. Hausman. He adds that increased intake of the nutrient is underscored by the recent "call to action" by several University of California researchers, who advise that most U.S. adults should consume 2,000 IU of vitamin D daily (1"The Tan Sheet" Nov. 17, 2008, In Brief)
Findings from two separate studies that suggest an increase in vitamin D intake can cut cancer risk by at least half may help "corral enough support" to look at increasing the upper intake level (UL)for vitamin D, according to Andrew Shao, Ph.D., VP scientific and regulatory affairs for the Council for Responsible Nutrition
Amneal has become the first company to secure US approval for, and to launch, a generic alternative to Merck & Co’s top-selling, off-patent NuvaRing contraceptive device in the US. Other generics developers appear to be several months behind.
Sign in to continue reading.
Need a specific report?
1000+ reports available
New to Pink Sheet?
Start a free trial today!
Register for our free email digests: